Navigation Links
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
Date:9/25/2007

LA JOLLA, Calif., Sept. 25 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced a one year extension of its research agreement with Eisai Co., Ltd. that was entered into on October 1, 2005. The extension marks the continuation of Eisai's support of Alzheimer's disease research at TorreyPines since 2001. This agreement, focusing on the discovery of Alzheimer's disease targets using whole-genome family-based association screening, is one of two TorreyPines discovery collaborations with Eisai in the field of Alzheimer's disease research. In a separate agreement, Eisai and TorreyPines are collaborating on the discovery of novel compounds to treat Alzheimer's disease.

The goal of the genetics research collaboration is to identify and validate genes associated with Alzheimer's disease as potential pharmaceutical targets. Under the terms of the agreement and in connection with the extension, TorreyPines will receive an upfront payment and continued research funding in support of the program for an additional year. In return, Eisai will continue to have exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research.

"We are pleased that Eisai, a leader in Alzheimer's disease research, has elected to continue their long-standing support of our genetics discovery program," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "The extension of our collaboration with Eisai not only validates the importance of this research, but also moves us one step closer to our goal of discovering new therapies for patients suffering from Alzheimer's disease."

The genetics research will be performed at TorreyPines in c
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Extended data analysis using DeCyder EDA
3. Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System
4. Techware to extend broadband wireless network to Butler
5. UW gets $5M to extend entrepreneurship
6. Creativity, innovation extend to municipalities
7. NimbleGen extends research market reach
8. TomoTherapy extends reach to Germany
9. Third Wave says patent extends IP reach
10. `Single-sales factor extends tax treatment to tech, service firms
11. Alumni Association extends database help to university

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ION -- Gone hybrid . . . , Fuel economy rating...posted at the www.fueleconomy.gov web site, whic...tains for the U.S. Department of Energy and the U....p 10 vehicles on the best fuel economy list are hy...ty; 48 highway). "This list proves that hybrids ha...
(Date:11/5/2009)... Nov. 5 Imagenetix, Inc....William Spencer, President and CEO of Imagenetix, ...annual LD MICRO Conference on Thursday, December 3...les. ,, About LD MICRO ,, LD MICRO is a by-i...ding undervalued companies in the micro-cap space....
(Date:11/5/2009)...N.Y., Nov. 5 BioSpecific...ceutical company developing first-in-class collage... results for the third quarter ended September 30,...ptember of this year, the FDA,s Arthritis Advisory...2-0, the approval of XIAFLEX(TM) for the treatment...
(Date:11/5/2009)...alif., Nov. 5 WaferGen B...ing developer of state-of-the-art genetic analysis...Ph.D. has joined the company,s Scientific Advisory...and commercializing novel molecular diagnostics fo...the development of computational biology systems f...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4
... This release is available in French . , An N...laid the groundwork for a lithium battery that can... of conventional lithium ion batteries. , The re...dent David Xiulei Ji and postdoctoral fellow Kyu T...electrochemical performance for a lithium-sulphur ...
... SEATTLE, May 18 /PRNewswire-FirstCall/ - Oncothyr...ced the presentation of data demonstrating the eff...l model of pulmonary fibrosis. The data were prese...ociate Professor, Pulmonary Medicine, Children,s H...merican Thoracic Society International Conference ...
... Non-Profit Biotech Calls on the Entire ALS Commun...ay Events , , CAMBRIDGE, Mass., May 18 The ALS ...its BBQ For ALS Awareness , is a national initiat...anding of ALS (amyotrophic lateral sclerosis), oth...h its goal, the campaign brings together three und...
Other Biology Technology:Canadian research team reports major breakthrough in lithium battery technology 2Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 2Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 3Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 2Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 3
(Date:11/4/2009)... DigitalPersona, Inc., a leader in ... today announced that WAND Corporation, a leading ...-service restaurants, has integrated DigitalPerson...S solutions. WAND,s quick-service customers can no...untability and deter unauthorized manager override...
(Date:11/4/2009)...re/ -- What,s the cost of saving a teenage life? W...ing from prescription medication abuse, there,s no... may be unaware that the lock-boxes they,ve instal...g timebomb of prescription drugs. That,s why MEDNE...l supplies, has formed an exclusive partnership wi...
(Date:11/4/2009)...e-FirstCall/ -- BIO-key International, Inc. (OTC B...metric identification software is showcasing donor...onference being held at the New Orleans Convention...ide hands-on product demonstrations of its state-o... Also, at 5 PM on Monday, October 26, Peter Lux, m...
Breaking Biology News(10 mins):WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3BIO-key(R) International Exhibiting at AABB TXPO 2Ohio Law Firm Warns of Birth Control Pill YAZ Yasmin Side Effects Lawsuits 54279 1Ohio Law Firm Warns of Birth Control Pill YAZ Yasmin Side Effects Lawsuits 54279 2Ohio Law Firm Warns of Birth Control Pill YAZ Yasmin Side Effects Lawsuits 54279 3Ohio Law Firm Warns of Birth Control Pill YAZ Yasmin Side Effects Lawsuits 54279 4Mysterious charge transport in self assembled monolayer transistors unraveled 13515 1Mysterious charge transport in self assembled monolayer transistors unraveled 13515 2Emdeon Inc Prices Initial Public Offering of Class A Common Stock at 2415 50 Per Share 54275 1Emdeon Inc Prices Initial Public Offering of Class A Common Stock at 2415 50 Per Share 54275 2Emdeon Inc Prices Initial Public Offering of Class A Common Stock at 2415 50 Per Share 54275 3Emdeon Inc Prices Initial Public Offering of Class A Common Stock at 2415 50 Per Share 54275 4
...ncestral line of parasitic bacteria, scientists ca...o revealed where you lived or who you spent time w...ow to look. , Stanford researchers with collabora...dation for opening such a window to the past using...ue uses genomic data to examine metabolic networks...
...cal model could be used to predict an individual,s...hildren,s Hospital Informatics Program (CHIP). Usi... the researchers showed that their predictive mode...ardioembolic stroke -- the most common form of str...reported in the March issue of Stroke . , "For c...
... warning signs of climate change in the upper atmo...e 2009 Tyler Prize for Environmental Achievement. ... and gold medals, will go to Richard Alley, profes...eerabhadran (Ram) Ramanathan, professor of atmosph...on of Oceanography at the University of California...
Other Biology News:Reversing ecology reveals ancient environments 2Predicting risk of stroke from one's genetic blueprint 2Winners of Tyler environmental prize announced 2
...Linear Ion Trap Time of Flight Mass Analyzer for s...power., Specifications:, * MS mode measurement r...range: 150 - 4000 m/z, * Resolution: 14,000 (1400 ...eference, * Dynamic range: 4 orders of magnitude ...
...lay Vector is specifically designed to target and ...charomyces cerevisiae. Displayed proteins can be a...r putative ligands. pYD1 uses the a-agglutinin yea..., Aga1 and Aga2, to display recombinant protein on...
...is a pleiotropic cytokine produced by activated T ...nhibits the growth of some tumour and normal cell ...osis sarcoma cell proliferation, cytokine release ... receptor expression on hepatoma cells. Mouse OSM ...
Mouse Anti-Human BTAF1 Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: